Current report
Open the filing on sec.gov
Citius Pharmaceuticals, Inc. (CTXR)
Nasdaq: CTXR · Pharmaceutical Preparations · Cranford, NJ · filing with the SEC since 2010
The companyfiscal 2022, as filed
Revenue$90,0000.0%
Net income-$33.6M-45.9%
Earnings per share$-5.750.0%
Operating cash flow-$28.4M-17.0%
Cash$41.7M-40.5%
Debtn/a
Shareholders’ equity$103M-22.2%
Shares, diluted5,843,296+34.5%
Return on equity-58.8%
The recordfrom its filings
Filings in 202630
Newest filingNov 4 · 8-K
Annual reportDec 23, 2025
Quarterly reportAug 14, 2026
Next report due10-K by Dec 29
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted0
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$58.2MCash from operations -$34.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
SEC comment letter
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Activist holder update, amended
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.